CYP2D6 and breast carcinoma: In a previous report of patients with breast cancer randomised to treatment with and without tamoxifen we found that genetic polymorphism in CYP2D6 and SULT1A1 may predict the benefit of tamoxifen therapy with a significantly improved disease-free survival in patients that were carriers of the CYP2D6*4 allele and/or were homozygous for the SULT1A1*1 allele [25].